(RS)-α-Methyl-3-carboxymethylphenylglycine
Discontinued Product
(RS)-α-Methyl-3-carboxymethylphenylglycine (Cat. No. 0856) has been withdrawn from sale for commercial reasons.
Biological Activity
Group I/group II mGlu antagonist at cloned receptors.
Technical Data
| M. Wt | 223.23 |
| Storage | Store at RT |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets
Please contact Customer Service
References
References are publications that support the biological activity of the product.
Bedingfield et al (1995) Structure-activity relationships for a series of phenylglycine derivatives at metabotropic glutamate receptors (mGluRs). Br.J.Pharmacol. 116 3323 PMID: 8719814
Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493 PMID: 8730745
Watkins and Collingridge (1994) Phenylglycine derivatives as antagonists of metabotropic glutamate receptors. TiPS 15 333 PMID: 7992387
View Related Products by Target
View Related Products by Product Action
Keywords: (RS)-a-Methyl-3-carboxymethylphenylglycine, (RS)-a-Methyl-3-carboxymethylphenylglycine supplier, Non-selective, mGlu, 0856, Tocris Bioscience
Citations for (RS)-α-Methyl-3-carboxymethylphenylglycine
Citations are publications that use Tocris products.
Currently there are no citations for (RS)-α-Methyl-3-carboxymethylphenylglycine.
Reviews for (RS)-α-Methyl-3-carboxymethylphenylglycine
There are currently no reviews for this product. Be the first to review (RS)-α-Methyl-3-carboxymethylphenylglycine and earn rewards!
Have you used (RS)-α-Methyl-3-carboxymethylphenylglycine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GPCR Product Listing
A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:
- Rhodopsin-like Receptors
- Secretin-like Receptors
- Glutamate Receptors
- Frizzled Receptors
- GPCR Signaling
Pain Research Product Guide
A collection of over 250 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Epilepsy Poster
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
